{"nctId":"NCT04029116","briefTitle":"Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)","startDateStruct":{"date":"2019-10-21","type":"ACTUAL"},"conditions":["Recurrent Vulvovaginal Candidiasis"],"count":440,"armGroups":[{"label":"Ibrexafungerp","type":"EXPERIMENTAL","interventionNames":["Drug: Fluconazole Tablet","Drug: IBREXAFUNGERP"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Fluconazole Tablet","Drug: Placebo oral tablet"]}],"interventions":[{"name":"Fluconazole Tablet","otherNames":[]},{"name":"IBREXAFUNGERP","otherNames":["SCY-078"]},{"name":"Placebo oral tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Diagnosis of symptomatic VVC with microscopic examination with KOH positive for yeast and normal vaginal pH.\n* History of 3 or more episodes of VVC in the past 12 months.\n* Culture confirmation and resolution of the signs and symptoms of the initial VVC episode (with treatment).\n* Able to take oral tablets and capsules.\n\nKey exclusion Criteria:\n\n* Vaginal conditions other than recurrent VVC that may interfere with the diagnosis or evaluation of response to therapy.\n* Recent use of systemic and/or topical vaginal antifungal products.\n* Pregnant.\n* History of major system organ disease.","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Success","description":"Efficacy as measured by the percentage of subjects with documented Clinical Success.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"69","spread":null}]},{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Subjects With no Mycologically Proven Recurrence","description":"Efficacy as measured by the percentage of subjects with no Mycologically Proven Recurrence","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"76","spread":null}]},{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability","description":"Safety as measured by the number of subjects who discontinue due to treatment related adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":130},"commonTop":["Headache","Bacterial vaginosis","Diarrhoea","Nausea","COVID-19"]}}}